GRAIL, LLC (GRAL NASDAQ) stock market data APIs
$47.0947
0.38(0.8%)
as of July 3, 2025
Try our APIs with
free plan!
GRAIL, LLC Financial Data Overview
Price chart is built with
Anychart
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Prev. Close
47.0947
Open
47.475
High
47.9165
Low
45.6539
52 wk Range
12.33-63.99
Market Cap
1 681 M
Shares Outstanding
35 974 K
Revenue
131 M
EPS
-3.1
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GRAIL, LLC data using free add-ons & libraries
Get GRAIL, LLC Fundamental Data
GRAIL, LLC Fundamental data includes:
- Net Revenue: 131 M
- EBITDA: -496 632 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -3.99
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GRAIL, LLC News
New
GRAIL Inc (GRAL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances
Revenue: $31.8 million, up 19% compared to Q1 2024. Screening Revenue: $29.1 million, up 24% compared to Q1 2024. Development Service Revenue: $2.7 million. US Galleri Revenue: $28.7 million, up 22% c...
Why GRAIL, Inc. (GRAL) is Surging in 2025
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where GRAIL, Inc. (NASDAQ:GRAL) stands against other healthcare stoc...
This Cancer Test Could Become Routine—and a Big Seller, Says Analyst
Grail cutting-edge cancer blood test has stirred investor excitement many times in the past few years. With the stock down 55% from its February peak, Canaccord Genuity issued a Buy recommendation on ...
Jim Cramer Likes GRAIL, Inc. (GRAL) Despite Losses – Great Science, Risky Bet!
We recently published a list of Jim Cramer Put These 16 Stocks Under a Microscope. In this article, we are going to take a look at where GRAIL, Inc. (NASDAQ:GRAL) stands against other stocks that Jim ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
